產(chǎn)品詳情
簡單介紹：
重組鼠遷移抑制因子蛋白與其它公司提供的重組蛋白不同，rMuMIF蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨有的全自動蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組鼠遷移抑制因子蛋白（全長序列）產(chǎn)品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組鼠遷移抑制因子蛋白
| Synonyms | MIF, DER6, GIF, L-dopachrome Isomerase, L-dopachrome Tautomerase, Phenylpyruvate Tautomerase |
| Species | Murine |
| Accession | P34884 |
| GeneID | 17319 |
| Source | 重組鼠遷移抑制因子蛋白Escherichia coli. |
| Molecular Weight | Approximately 12.5 kDa, a single non-glycosylated polypeptide chain containing 115 amino acids. |
| Quantity | 10μg/50μg/1000μg |
| AA Sequence | MPMFIVNTNV PRASVPEGFL SELTQQLAQA TGKPAQYIAV HVVPDQLMTF SGTNDPCALC SLHSIGKIGG AQNRNYSKLL CGLLSDRLHI SPDRVYINYY DMNAANVGWN GSTFA |
| Purity | 重組鼠遷移抑制因子蛋白> 96 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | Bioassay data are not available. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4, 1 mM DTT. |
| Endotoxin | Less than 1 EU/μg of rMuMIF as determined by LAL method. |
| Reconstitution | 重組鼠遷移抑制因子蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組鼠遷移抑制因子蛋白 | |
| SDS-PAGE |
|
| Reference |
1. WY Weiser, PA Temple, JS Witek-Giannotti, et al. 1989. Proc Natl Acad Sci U S A, 86: 7522-6. 2. CA Kozak, MC Adamson, CE Buckler, et al. 1995. Genomics, 27: 405-11. 3. DF LarsonandK Horak. 2006. Crit Care, 10: 138. 4. HW Sun, J Bernhagen, R Bucala, et al. 1996. Proc Natl Acad Sci U S A, 93: 5191-6. 5. M Oddo, T Calandra, R Bucala, et al. 2005. Infect Immun, 73: 3783-6. 6. M Emonts, FC Sweep, N Grebenchtchikov, et al. 2007. Clin Infect Dis, 44: 1321-8. 7. J Bernhagen, RA Mitchell, T Calandra, et al. 1994. Biochemistry, 33: 14144-55. |
| Background | Macrophage migration inhibitory factor (MIF or MMIF), also named as glycosylation-inhibiting factor (GIF), L-dopachrome isomerase, or phenylpyruvate tautomerase, is a protein encoded by the MIF gene. It is released from white blood cells by bacterial antigen stimulation to trigger an acute immune response, or by glucocorticoids to counter-act the inhibitory effects of glucocorticoids on immune system. MIF is a homotrimer of which each subunit contains 115 amino acids. As mentioned above, MIF is involved in the innate immune response to bacterial pathogens and counter-acts the anti-inflammatory activity of glucocorticoids. Furthermore, it also plays a role as mediator in regulating the function of macrophages in host defense and has phenylpyruvate tautomerase and dopachrome tautomerase activity in vitro. Mouse MIF is active on human cells, while human MIF is active on mouse cells. Mouse MIF is 99 %, 84 %, 90 %, and 90 % a.a. identical to rat, porcine, bovine and human MIF, respectively. |
